Evolving Therapeutics

evolvingtherapeutics.es ↗ ·Valencia ·Pre-seed

Evolving Therapeutics is a biotech spin-off of the Universitat de València that develops bacteriophage-based solutions for the prevention, diagnosis and treatment of multidrug-resistant bacteria, under a One Health approach spanning human, animal and plant health. Founded in 2023 by sisters Marisa and Pilar Domingo-Calap, it operates from the Parc Científic of the Universitat de València in Paterna (Valencia) and claims the first commercial personalised phage-therapy service in Spain. It closed a €100K round from Angels (Juan Roig's investment vehicle) in January 2025, was accelerated by Lanzadera, and won the 2026 EmprendeXXI award for the Valencian Community.

Founded

2023

Founders

Total funds raised

€100K

SectorsBiotech, Phage therapy, Antimicrobial resistance, Healthtech, Agtech, Animal health Start-up MapHealthtech & Bio › Drug discovery & therapeutics developers

Suggest a correction

Founders

Marisa Domingo-Calap

Co-founder & CEO

Pilar Domingo-Calap

Co-founder & Chief Scientific Officer

Global models 5

SNIPR Biome

Denmark · www.sniprbiome.com ↗

Builds phage-based (CRISPR-armed) therapeutics that selectively kill drug-resistant bacteria, the same phage-against-AMR approach Evolving Therapeutics takes.

~$90MComparable

BiomX

Israel · www.biomx.com ↗

Develops natural and engineered phage cocktails against specific pathogens such as resistant Pseudomonas and Staphylococcus, mirroring Evolving's phage-therapy pipeline.

~$75MComparable

Adaptive Phage Therapeutics

United States · www.aphage.com ↗

Runs a phage bank that matches personalised phage treatments to each patient's resistant infection, which is closest to Evolving's personalised phage-therapy service.

~$60MComparable

Eligo Bioscience

France · eligo.bio ↗

Uses phage-derived delivery vehicles to precisely remove harmful bacteria, applying phage biology to bacterial disease as Evolving does.

~$55MComparable

Locus Biosciences

United States · www.locus-bio.com ↗

Develops CRISPR-enhanced bacteriophage therapies against multidrug-resistant infections, funded by VC plus pharma and BARDA contracts.

~$40MComparable

In the same niche 67 others

See all in the Start-ups Map →

Highlight Therapeutics

+61 more →

Notes: Most funded first

Investors 3

Open as list →

Angels Capital

www.angelscapital.es

Led Pre-seed 2025 Spain

Lanzadera

lanzadera.es

Investor Spain

Universitat de València

www.uv.es ↗

Investor Spain

Funding rounds 1

Date	Round	Amount	Lead
2025-01-21	Pre-seed (estimated)	€100K	Angels Capital

News 7

Open as list →

Published	Article
2026-04-16	Evolving Therapeutics gana los Premios EmprendeXXI en la Comunidad Valenciana como la startup con mayor potencial ↗ El Independiente 2026-04-16
2026-01-12	Evolving Therapeutics, awarded at the Expansión Start Up Awards ↗ PCUV News (Science Park, University of Valencia) 2026-01-12
2025-06-18	ARTHEx Biotech, Evolving Therapeutics and Optical Sens, awarded at the Santander X 2025 awards in the Startup category ↗ PCUV News (Science Park, University of Valencia) 2025-06-18
2025-01-21	Evolving Therapeutics spin-off receives private funding from Angels to tackle multidrug-resistant bacteria with phages ↗ Universitat de València 2025-01-21
2024-11-29	Pioneering research by the University and the CSIC uses bacteria viruses against Xylella fastidiosa in the Balearic Islands ↗ I2SysBio (CSIC–Universitat de València) 2024-11-29
2024-03-21	Evolving Therapeutics, la startup que combate bacterias multirresistentes con virus que se las comen ↗ Innovaspain 2024-03-21
2023-05-19	EVOLVING THERAPEUTICS, new biotech spin-off of the University of Valencia located at I2SysBio ↗ PCUV News (Science Park, University of Valencia) 2023-05-19